SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (157)12/28/2005 3:52:26 PM
From: Rudy Saucillo  Read Replies (1) of 332
 
>>Majority, if not all, animal studies were with very high drug dose, so data are irrelevant, imo.<<

I ran across the minutes from the 2002 American Chemical Society meeting. During this meeting, Charles Meng, an AGIX scientist, described the research that led to the derivation of 1067 and described the 1-year hypercholesterolemic monkey study. For the hypercholesterolemic monkey study, Meng reported that the 150 mg/kg/day dosage yielded plasma concentrations similar to humans at 280 kg/day (although this is not mentioned in the C. Sundell, P. Somers paper that documents the animal studies).

64.233.167.104
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News